DK2978859T3 - Genetiske markører til forudsigelse af responsivitet på terapi - Google Patents
Genetiske markører til forudsigelse af responsivitet på terapi Download PDFInfo
- Publication number
- DK2978859T3 DK2978859T3 DK14714628.6T DK14714628T DK2978859T3 DK 2978859 T3 DK2978859 T3 DK 2978859T3 DK 14714628 T DK14714628 T DK 14714628T DK 2978859 T3 DK2978859 T3 DK 2978859T3
- Authority
- DK
- Denmark
- Prior art keywords
- hdl
- dalcetrapib
- use according
- raising
- rsl967309
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
- C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
Claims (25)
1. HDL-hævende eller HDL-imiterende middel til anvendelse ved behandling af kardiovaskulær lidelse, hvor de behandlede individer har en forbedret responsgenotype på et eller flere af følgende steder: rsl967309, rsl2595857,rs2239310,rs 11647828, rs8049452, rsl2935810, rs74702385, rsl7136707 rs8061182, rsl 11590482, rs4786454, rs2283497, rs2531967, rs3730119, rsl3337675, rsl2920508, rsl2599911, rs2531971 eller rs2238448, hvor det "HDL-hævende eller HDL-imiterende middel" er dalcetrapib.
2. HDL-hævende eller HDL-imiterende middel til anvendelse ved behandling af kardiovaskulær lidelse ifølge krav 1, hvor de behandlede individer har en forbedret responsgenotype på et eller flere af følgende steder: rsl967309, rsl2595857, rs2239310, rsl 1647828, rs8049452, rsl2935810, rs74702385, rsl7136707, rs8061182, rsl 11590482, rs4786454, rs2283497, rs2531967, rs3730119 eller rsl3337675.
3. Thioisosmørsyre S-(2- {[ 1 -(2-ethylbutyl)-cyclohexancarbonyl]-amino} -phenyl)- ester til anvendelse ved behandling af en patient med kardiovaskulær lidelse, hvilken patient bærer en forbedret responsgenotype, hvor genotypen er valgt blandt rsl2595857/GG, rsl967309/AA, rsl 11590482/AG, rsl 11590482/GG, rsl 1647828/GG, rsl2935810/GG, rsl7136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG og rs8061182/AA.
4. HDL-hævende eller HDL-imiterende middel til anvendelse ifølge krav 2, hvor det behandlede individ har en forbedret responsgenotype rsl967309.
5. HDL-hævende eller HDL-imiterende middel til anvendelse ifølge krav 4, hvor genotypen er AA.
6. HDL-hævende- eller HDL-imiterende middel til anvendelse ifølge krav 4 eller 5, hvor den kardiovaskulære lidelse er valgt fra gruppen bestående af aterosklerose, perifer vaskulær sygdom, dyslipidæmi, hyperbetalipoproteinæmi, hypoalphalipoproteinæmi, hyperkolesterolæmi, hypertriglyceridæmi, familiær hyperkolesterolæmi, angina, iskæmi, iskæmisk hjertesygdom, slagtilfælde, myokardieinfarkt, reperfusionsskade, angioplastisk restenose, hypertension og vaskulære komplikationer af diabetes, fedme eller endotoxæmi hos et pattedyr.
7. HDL-hævende eller HDL-imiterende middel til anvendelse ifølge et af kravene 4 eller 6, hvor den kardiovaskulære lidelse er valgt fra gruppen bestående af kardiovaskulær sygdom, ko ronar hjertesygdom, koronar arteriesygdom, hypoalphalipoproteinæmi, hyperbetalipoproteinæmi, hyperkolesterolæmi, hyperlipidæmi, aterosklerose, hypertension, hypertriglyceridæmi, hyperlipidoproteinæmi, perifer vaskulær sygdom, angina, iskæmi og myokardieinfarkt.
8. Thioisosmørsyre S-(2- {[ 1 -(2-ethylbutyl)-cyclohexancarbonyl]-amino} -phenyl)-ester til anvendelse ifølge krav 3, hvor den forbedrede responsgenotype er rsl967309/AA.
9. Thioisosmørsyre S-(2-{[ 1 -(2-ethylbutyl)-cyclohexancarbonyl]-amino}-phenyl)- ester til anvendelse ifølge krav 3 eller 8, hvor den kardiovaskulære lidelse er valgt fra gruppen bestående af aterosklerose, perifer vaskulær sygdom, dyslipidæmi, hyperbetalipoproteinæmi, hypoalphalipoproteinæmi, hyperkolesterolæmi, hypertriglyceridæmi, familiær hyperkolesterolæmi, angina, iskæmi, iskæmisk hjertesygdom, slagtilfælde, myokardieinfarkt, reperfusionsskade, angioplastisk restenose, hypertension og vaskulære komplikationer af diabetes, fedme eller endotoxæmi hos et pattedyr.
10. Thioisosmørsyre S-(2- {[ 1 -(2-ethylbutyl)-cyclohexancarbonyl]-amino} -phenyl)-ester til anvendelse ifølge et af kravene 3 eller 9, hvor den kardiovaskulære lidelse er valgt fra gruppen bestående af kardiovaskulær sygdom, koronar hjertesygdom, koronar arteriesygdom, hypoalphalipoproteinæmi, hyperbetalipoproteinæmi, hyperkolesterolæmi, hyperlipidæmi, aterosklerose, hypertension, hypertriglyceridæmi, hyperlipidoproteinæmi, perifer vaskulær sygdom, angina, iskæmi og myokardieinfarkt.
11. Dalcetrapib til anvendelse ved behandling af en kardiovaskulær lidelse hos et individ, der er blevet identificeret som havende en forbedret responsgenotype på et eller flere polymorfe steder i individets ADCY9-gen.
12. Dalcetrapib til anvendelse ifølge krav 11, hvor det ene eller flere polymorfe steder er et eller flere af: rsl967309, rsl2595857, rs2239310, rsl 1647828, rs8049452, rsl2935810, rs74702385, rsl7136707, rs8061182, rsl 11590482, rs4786454, rs2283497, rs2531967, rs3730119, rsl3337675, rsl2920508, rsl2599911, rs2531971 og rs2238448.
13. Dalcetrapib til anvendelse ifølge krav 12, hvor det ene eller flere polymorfe steder er et eller flere af rsl967309, rsl2595857, rs2239310, rsl 1647828, rs8049452, rsl2935810, rs74702385, rsl7136707, rs8061182, rsl 11590482, rs4786454, rs2283497, rs2531967, rs3730119 og rsl3337675.
14. Dalcetrapib til anvendelse ifølge krav 11 eller 13, hvor de forbedrede responsgenotyper er en eller flere af rsl967309/AA, rsl967309/AG, rsl2595857/GG, rsl259587/AG, rsl 11590482/AG, rsl 11590482/GG, rsl 1647828/GG, rsl 1647828/AG, rsl2935810/GG, rsl7136707/GG, rsl7136707/AG, rs2239310/GG, rs2239310/AG, rs2283497/AA, rs2283497/CA, rs2531967/AA, rs2531967/GA, rs3730119/AA, rs3730119/GA, rs4786454/AA, rs4786454/GA, rs74702385/GA, rs74702385/AA, rs8049452/GG, rs8049452/GA, rs8061182/AA, rs8061182/AG, rsl3337675/AG og rs3337675/GG.
15. Dalcetrapib til anvendelse ifølge krav 11 eller 13, hvor de forbedrede responsgenotyper er en eller flere af rsl967309/AA, rsl2595857/GG, rsl 11590482/AG, rsl 11590482/GG, rsl 1647828/GG, rsl2935810/GG, rsl7136707/GG, rs2239310/GG, rs2283497/AA, rs2531967/AA, rs3730119/AA, rs4786454/AA, rs74702385/GA, rs74702385/AA, rs8049452/GG og rs8061182/AA.
16. Dalcetrapib til anvendelse ifølge krav 11 eller 13, hvor de forbedrede responsgenotyper er en eller begge af rsl967309/AA og rsl2595857/GG.
17. Dalcetrapib til anvendelse ifølge krav 11 eller 13, hvor den forbedrede responsgenotype er rsl967309/AA.
18. Dalcetrapib til anvendelse ifølge et af kravene 11-17, hvor den kardiovaskulære lidelse er kardiovaskulær sygdom, koronar hjertesygdom, koronar arteriesygdom, hypoalphalipoproteinæmi, hyperbetalipoproteinæmi, hyperkolesterolæmi, hyperlipidæmi, aterosklerose, hypertension, hypertriglyceridæmi, hyperlipidoproteinæmi, perifer vaskulær sygdom, angina, iskæmi, akut koronarsyndrom eller myokardieinfarkt.
19. Dalcetrapib til anvendelse ved reduktion af risikoen for en kardiovaskulær hændelse i et individ, der er blevet identificeret som havende en forbedret responsgenotype på et eller flere polymorfe steder i individets ADCY9-gen.
20. Dalcetrapib til anvendelse ifølge krav 19, hvor den forbedrede responsgenotype er en eller begge af rsl967309 og rsl2595857.
21. Dalcetrapib til anvendelse ifølge krav 19, hvor den forbedrede responsgenotype er en eller begge af rsl967309/AA og rsl2595857/GG.
22. Dalcetrapib til anvendelse ifølge krav 20 eller 21, hvor den forbedrede responsgenotype er rsl967309/AA.
23. Dalcetrapib til anvendelse ifølge et af kravene 19 til 22, hvor den kardiovaskulære hændelse er kardiovaskulær død, ikke-dødelig myokardieinfarkt, ikke-dødeligt slagtilfælde af iskæmisk oprindelse, indlæggelse for ustabil angina eller koronar revaskularisering.
24. Dalcetrapib til anvendelse ifølge et af kravene 19 til 23, hvor individet har en kardiovaskulær lidelse.
25. Dalcetrapib til anvendelse ifølge et af kravene 19 til 23, hvor den kardiovaskulære lidelse er kardiovaskulær sygdom, koronar hjertesygdom, koronar arteriesygdom, hypoalphalipoproteinæmi, hyperbetalipoproteinæmi, hyperkolesterolæmi, hyperlipidæmi, aterosklerose, hypertension, hypertriglyceridæmi, hyperlipidoproteinæmi, perifer vaskulær sygdom, angina, iskæmi, akut koronarsyndrom eller myokardieinfarkt.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13161386 | 2013-03-27 | ||
| PCT/EP2014/055790 WO2014154606A1 (en) | 2013-03-27 | 2014-03-24 | Genetic markers for predicting responsiveness to therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2978859T3 true DK2978859T3 (da) | 2018-09-03 |
Family
ID=47997187
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14714628.6T DK2978859T3 (da) | 2013-03-27 | 2014-03-24 | Genetiske markører til forudsigelse af responsivitet på terapi |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US9909178B2 (da) |
| EP (2) | EP3404115A1 (da) |
| JP (2) | JP6449235B2 (da) |
| KR (1) | KR102153557B1 (da) |
| CN (2) | CN111073974B (da) |
| BR (1) | BR112015024116A2 (da) |
| CA (1) | CA2897420C (da) |
| DK (1) | DK2978859T3 (da) |
| ES (1) | ES2685269T3 (da) |
| HK (1) | HK1213602A1 (da) |
| HR (1) | HRP20181358T1 (da) |
| HU (1) | HUE039973T2 (da) |
| LT (1) | LT2978859T (da) |
| MX (2) | MX370538B (da) |
| PL (1) | PL2978859T3 (da) |
| PT (1) | PT2978859T (da) |
| RS (1) | RS57640B1 (da) |
| RU (1) | RU2707533C2 (da) |
| SI (1) | SI2978859T1 (da) |
| WO (1) | WO2014154606A1 (da) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2118074T3 (pl) | 2007-02-01 | 2014-06-30 | Resverlogix Corp | Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego |
| US9238640B2 (en) | 2009-03-18 | 2016-01-19 | Resverlogix Corp. | Anti-inflammatory agents |
| PT2978859T (pt) | 2013-03-27 | 2018-10-04 | Hoffmann La Roche | Marcadores genéticos para previsão da capacidade de resposta à terapêutica |
| RU2703192C2 (ru) | 2014-07-30 | 2019-10-15 | Ф. Хоффманн-Ля Рош Аг | Генетические маркеры для прогнозирования ответа на терапию поднимающими уровень hdl или имитирующими hdl агентами |
| CN114984016A (zh) | 2015-03-13 | 2022-09-02 | 雷斯韦洛吉克斯公司 | 用于治疗补体相关疾病之组合物及治疗方法 |
| US20190070178A1 (en) | 2017-08-29 | 2019-03-07 | Dalcor Pharma Uk Ltd., Stockport Zug Branch | Methods for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events |
| CN108004312B (zh) * | 2017-12-20 | 2019-01-01 | 德诺杰亿（北京）生物科技有限公司 | 检测心血管疾病相关基因多态性的引物组、试剂盒及方法 |
| KR20210044252A (ko) * | 2018-08-09 | 2021-04-22 | 달코어 파마 유케이 리미티드 레더헤드 저그 브랜치 | 신규 발병 제 2 형 당뇨병의 발생을 지연시키고 제 2 형 당뇨병의 진행을 늦추고 치료하는 방법 |
| KR20210137442A (ko) | 2019-03-07 | 2021-11-17 | 달코어 파마 유케이 리미티드 레더헤드 저그 브랜치 | 심부전을 치료 또는 예방하고 심부전의 위험을 감소시키는 방법 |
| WO2021140358A1 (en) * | 2020-01-08 | 2021-07-15 | Universitatea De Medicina Şi Farmacie "Victor Babes" (In English: University Of Medicine And Pharmacy "Victor Babes") | Method to identify patients who would respond favourably to hypolipidemic treatment |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2894445B2 (ja) | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Ｃｅｔｐ活性阻害剤として有効な化合物 |
| HU228892B1 (en) | 1999-06-04 | 2013-06-28 | Consejo Superior Investigacion | High oleic high stearic plants, seeds and oils |
| US20030092647A1 (en) | 2001-08-08 | 2003-05-15 | Crooke Rosanne M. | Antisense modulation of cholesteryl ester transfer protein expression |
| AU2002323270A1 (en) | 2001-08-18 | 2003-03-03 | Myriad Genetics, Inc | Composition and method for treating hiv infection |
| US20040180370A1 (en) * | 2003-01-27 | 2004-09-16 | The Regents Of The University Of Colorado, A Body Corporate | Genetic diagnosis of alcoholism subtypes |
| MXPA05009976A (es) | 2003-03-17 | 2005-11-04 | Japan Tobacco Inc | Metodo para incrementar la biodisponibilidad oral del 2-metilpropantioato de s-[2-([[1- 2-etilbutil) ciclohexil] carbonil] amino) fenilo]. |
| TWI393560B (zh) | 2003-05-02 | 2013-04-21 | Japan Tobacco Inc | 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合 |
| WO2005007111A2 (en) | 2003-07-11 | 2005-01-27 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
| US7326706B2 (en) | 2003-08-15 | 2008-02-05 | Bristol-Myers Squibb Company | Pyrazine modulators of cannabinoid receptors |
| CA2554982A1 (en) | 2003-09-26 | 2005-04-07 | Japan Tobacco Inc. | Method of inhibiting remnant lipoprotein production |
| US7517900B2 (en) | 2003-10-10 | 2009-04-14 | Bristol-Myers Squibb Company | Pyrazole derivatives as cannabinoid receptor modulators |
| WO2011008992A2 (en) | 2009-07-15 | 2011-01-20 | The Regents Of The University Of California | Peptides whose uptake in cells is controllable |
| US7420059B2 (en) | 2003-11-20 | 2008-09-02 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
| PT1697370E (pt) | 2003-12-19 | 2007-05-31 | Bristol Myers Squibb Co | Heterociclos azabicíclicos como moduladores do receptor de canabinóides |
| PL1697371T3 (pl) | 2003-12-19 | 2007-09-28 | Bristol Myers Squibb Co | Azabicykliczne heterocykle jako modulatory receptora kanabinoidowego |
| WO2005097261A1 (en) | 2004-03-30 | 2005-10-20 | Sapphire Therapeutics, Inc. | Method of reducing c-reactive protein using growth hormone secretagogues |
| US7375112B2 (en) | 2005-01-05 | 2008-05-20 | Medicure International Inc. | Compounds and methods for regulating triglyceride levels |
| WO2006099142A2 (en) * | 2005-03-10 | 2006-09-21 | The Trustees Of Boston University | Prognostic method for vascular diseases |
| JP2006288279A (ja) * | 2005-04-11 | 2006-10-26 | Otsuka Pharmaceut Co Ltd | 出血時間延長傾向判定方法 |
| CN101291662A (zh) | 2005-10-21 | 2008-10-22 | 诺瓦提斯公司 | 肾素抑制剂和抗血脂异常剂和/或抗肥胖剂的组合 |
| US7435849B2 (en) | 2005-10-31 | 2008-10-14 | Hoffmann-La Roche Inc. | Process for the production of acid chlorides |
| AU2006313430B2 (en) | 2005-11-08 | 2012-09-06 | Ranbaxy Laboratories Limited | Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
| US20070213274A1 (en) * | 2005-12-20 | 2007-09-13 | Oy Jurilab Ltd | Novel genes and markers associated with high-density lipoprotein-cholesterol (HDL-C) |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| US20090035306A1 (en) | 2006-11-29 | 2009-02-05 | Kalypsys, Inc. | Quinazolinone modulators of tgr5 |
| EP1935867A1 (en) | 2006-12-20 | 2008-06-25 | F. Hoffmann-La Roche Ag | Process for preparing 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid |
| WO2008097976A1 (en) | 2007-02-09 | 2008-08-14 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 for treatment of disease |
| JP5314671B2 (ja) | 2007-04-25 | 2013-10-16 | エフ．ホフマン−ラ ロシュ アーゲー | 酸塩化物の新規合成方法 |
| US20090054304A1 (en) | 2007-08-23 | 2009-02-26 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 for treatment of disease |
| US20090105124A1 (en) | 2007-08-23 | 2009-04-23 | Kalypsys, Inc. | Heterocyclic modulators of tgr5 |
| ES2592727T3 (es) | 2008-04-04 | 2016-12-01 | F. Hoffmann-La Roche Ag | Nuevo proceso para la preparación de derivados del ácido ciclohexanocarboxílico |
| ES2460900T3 (es) | 2008-04-04 | 2014-05-14 | F. Hoffmann-La Roche Ag | Nuevo procedimiento para la preparación de derivados de ácido ciclohexanocarboxílico mediante el correspondiente derivado ciclohexanocarboxamida |
| ES2624716T3 (es) | 2008-06-17 | 2017-07-17 | F. Hoffmann-La Roche Ag | Éster del ácido 1-(2-etil-butil)-ciclohexanocarboxílico como intermedio en la preparación de amidas farmacéuticamente activas |
| EP2177615A1 (en) * | 2008-10-10 | 2010-04-21 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases |
| WO2010056910A2 (en) | 2008-11-12 | 2010-05-20 | Carolus Therapeutics, Inc. | Methods of treating cardiovascular disorders |
| BRPI0922888A2 (pt) | 2008-12-08 | 2019-09-24 | Hoffmann La Roche | administração combinada de fármaco |
| NZ720946A (en) | 2009-04-29 | 2017-09-29 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
| US20110004011A1 (en) | 2009-07-01 | 2011-01-06 | Declan Costello | Novel process |
| WO2012012870A1 (en) | 2010-07-28 | 2012-02-02 | Institut De Cardiologie De Montreal | Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction comprising an apolipoprotein peptide/phospholipid complex |
| EP2616433B1 (en) | 2010-09-16 | 2015-12-09 | F.Hoffmann-La Roche Ag | Process for preparing a cyclohexanecarbonitrile derivative |
| CN105833283A (zh) | 2010-11-04 | 2016-08-10 | 霍夫曼-拉罗奇有限公司 | 包含2-甲基丙硫代酸s-[2-([[1-(2-乙基丁基)-环己基]-羰基]氨基)苯基]酯和交联羧甲基纤维素钠的组合物 |
| EP2648698A1 (en) | 2010-12-08 | 2013-10-16 | F.Hoffmann-La Roche Ag | Liposomal formulation of dalcetrapib |
| KR101947840B1 (ko) | 2010-12-16 | 2019-02-13 | 에프. 호프만-라 로슈 아게 | 다이설파이드의 수소화에 의한 방향족 티올 유도체의 제조 방법 |
| US20140044668A1 (en) * | 2011-02-15 | 2014-02-13 | The Ohio State University | Methods for Predicting Cardiovascular Risks and Responsiveness to Statin Therapy Using SNPs |
| RU2013139701A (ru) * | 2011-02-17 | 2015-03-27 | Ф. Хоффманн-Ля Рош Аг | Способ контролируемой кристаллизации активного фармацевтического ингредиента из состояния переохлажденной жидкости экструзией горячего распада |
| US9541565B2 (en) | 2011-04-08 | 2017-01-10 | Zora Biosciences Oy | Biomarkers for sensitive detection of statin-induced muscle toxicity |
| JP5980900B2 (ja) | 2011-04-08 | 2016-08-31 | ゾラ バイオサイエンシーズ オサケ ユキチュア | スタチン誘発性筋毒性の高感度検出のためのバイオマーカー |
| US20120301439A1 (en) | 2011-05-24 | 2012-11-29 | Washington University | Inhibition of choroidal neovascularization |
| US8975438B2 (en) | 2011-07-13 | 2015-03-10 | Hoffmann-La Roche Inc. | Process for the preparation of cyclohexanecarboxylic acid derivatives |
| AR089853A1 (es) | 2012-02-01 | 2014-09-24 | Boehringer Ingelheim Int | Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso |
| EP2822941B1 (en) | 2012-03-06 | 2017-05-10 | Boehringer Ingelheim International GmbH | Benzodioxanes in combination with statins for inhibiting leukotriene production |
| WO2013164257A1 (en) | 2012-04-30 | 2013-11-07 | F. Hoffmann-La Roche Ag | New formulation |
| MX351059B (es) | 2012-08-17 | 2017-09-29 | Laboratorios Senosiain S A De C V Star | Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion. |
| PT2978859T (pt) | 2013-03-27 | 2018-10-04 | Hoffmann La Roche | Marcadores genéticos para previsão da capacidade de resposta à terapêutica |
| KR20160093024A (ko) | 2013-12-19 | 2016-08-05 | 에프. 호프만-라 로슈 아게 | 눈 질환의 치료에 사용하기 위한 cetp 조절제 |
| RU2703192C2 (ru) | 2014-07-30 | 2019-10-15 | Ф. Хоффманн-Ля Рош Аг | Генетические маркеры для прогнозирования ответа на терапию поднимающими уровень hdl или имитирующими hdl агентами |
| US20190070178A1 (en) | 2017-08-29 | 2019-03-07 | Dalcor Pharma Uk Ltd., Stockport Zug Branch | Methods for treating or preventing cardiovascular disorders and lowering risk of cardiovascular events |
| KR20210044252A (ko) * | 2018-08-09 | 2021-04-22 | 달코어 파마 유케이 리미티드 레더헤드 저그 브랜치 | 신규 발병 제 2 형 당뇨병의 발생을 지연시키고 제 2 형 당뇨병의 진행을 늦추고 치료하는 방법 |
-
2014
- 2014-03-24 PT PT14714628T patent/PT2978859T/pt unknown
- 2014-03-24 CN CN201911328044.6A patent/CN111073974B/zh active Active
- 2014-03-24 JP JP2016504603A patent/JP6449235B2/ja active Active
- 2014-03-24 RU RU2015145133A patent/RU2707533C2/ru active
- 2014-03-24 SI SI201430853T patent/SI2978859T1/sl unknown
- 2014-03-24 ES ES14714628.6T patent/ES2685269T3/es active Active
- 2014-03-24 CN CN201480017986.1A patent/CN105164276B/zh active Active
- 2014-03-24 CA CA2897420A patent/CA2897420C/en active Active
- 2014-03-24 WO PCT/EP2014/055790 patent/WO2014154606A1/en active Application Filing
- 2014-03-24 HU HUE14714628A patent/HUE039973T2/hu unknown
- 2014-03-24 LT LTEP14714628.6T patent/LT2978859T/lt unknown
- 2014-03-24 EP EP18176394.7A patent/EP3404115A1/en active Pending
- 2014-03-24 RS RS20180997A patent/RS57640B1/sr unknown
- 2014-03-24 BR BR112015024116A patent/BR112015024116A2/pt not_active Application Discontinuation
- 2014-03-24 EP EP14714628.6A patent/EP2978859B1/en active Active
- 2014-03-24 KR KR1020157026058A patent/KR102153557B1/ko active IP Right Grant
- 2014-03-24 DK DK14714628.6T patent/DK2978859T3/da active
- 2014-03-24 PL PL14714628T patent/PL2978859T3/pl unknown
- 2014-03-24 MX MX2015013505A patent/MX370538B/es active IP Right Grant
-
2015
- 2015-09-22 MX MX2019015058A patent/MX2019015058A/es unknown
- 2015-09-23 US US14/863,148 patent/US9909178B2/en active Active
-
2016
- 2016-02-11 HK HK16101496.9A patent/HK1213602A1/zh unknown
-
2018
- 2018-01-22 US US15/877,019 patent/US20180155784A1/en not_active Abandoned
- 2018-08-22 US US16/109,447 patent/US10711303B2/en active Active
- 2018-08-24 HR HRP20181358TT patent/HRP20181358T1/hr unknown
- 2018-12-05 JP JP2018228045A patent/JP2019058180A/ja active Pending
-
2020
- 2020-06-03 US US16/891,493 patent/US11549142B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11549142B2 (en) | CETP inhibitors for therapeutic use | |
| US11401554B2 (en) | Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent | |
| RU2809215C2 (ru) | Генетические маркеры для прогнозирования восприимчивости к терапии | |
| BR112017001785B1 (pt) | Marcadores genéticos para predição de responsividade à terapia com agente de elevação de hdl ou imitação de hdl |